Latest News of CYTO
Cytokinetics, Incorporated (CYTK) Stock Price, News, Quote & History
By Yahoo! Finance |
3 days ago
Bayer has acquired rights to Cytokinetics' heart drug in Japan through a collaboration deal. The agreement includes an upfront payment of 50 million euros with potential additional payments based on d...
Bayer acquires rights to Cytokinetics' heart drug in Japan
By Yahoo! Finance |
3 days ago
Bayer collaborates with U.S. biotech firm Cytokinetics to acquire rights in Japan for an experimental heart drug, strengthening its cardiovascular business. The deal includes upfront payment of 50 mil...
CytomX Therapeutics Inc (CTMX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ...
By Yahoo! Finance |
2 weeks ago
The CEO, Sean McCarthy, provided updates on CX-904 and CX-2051 programs, emphasizing dose escalation for CX-904 and progress into cohort five for CX-2051. Phase 1B decisions and updates are expected n...
-
Is Cytokinetics Inc. (CYTK) Positioned for Success with Its Innovative Muscle Modulators?
By Yahoo! Finance | 1 month agoA recent article highlights Cytokinetics Inc. as a promising small-cap stock for investment. It discusses the impact of interest rate cuts on small and mid-cap stocks and provides insights from expert...
-
Cytokinetics, Incorporated (CYTK) Stock Price, News, Quote & History - Yahoo Finance
By Yahoo! Finance | 2 months agoCytokinetics, Inc. shared positive results from the Phase 1 study of CK-4021586 at a medical conference. The study successfully evaluated safety, tolerability, and pharmacokinetics of CK-586, a drug b...
-
Is Cytokinetics, Incorporated (CYTK) a Good Biotech Stock According to Hedge Funds?
By Yahoo! Finance | 2 months agoA compilation of the 12 Best Biotech Stocks To Invest In According To Hedge Funds includes Cytokinetics, Inc. (NASDAQ:CYTK). The biotech industry is forecasted to grow significantly, with AI-driven dr...
-
Cytokinetics Shows Market Leadership With Jump To 82 RS Rating
By Investor's Business Daily | 3 months agoLearn about managing stock market exposure with incremental portfolio decisions using IBD's RS Rating. Discover how to use risk management strategies and analyze stock performance, like Cytokinetics, ...
-
Investors in Cytokinetics (NASDAQ:CYTK) have seen incredible returns of 381% over the past five years
By Yahoo! Finance | 3 months agoLong term investing in great businesses like Cytokinetics (NASDAQ:CYTK) can lead to significant share price growth, with a 381% gain in the last five years. Despite not being profitable, its 6.7% annu...
-
Cytokinetics Clears Technical Benchmark, Hitting 80-Plus RS Rating
By Investor's Business Daily | 3 months agoLearn how to manage your stock market exposure with incremental decisions using a unique rating system. Understand the importance of RS Rating and risk management. Discover insights on Cytokinetics an...
-
CytomX Therapeutics, Inc. (CTMX): The Best One-Dollar Stock to Buy Now?
By Yahoo! Finance | 3 months agoThe article discusses the current stock market trends and focuses on CytomX Therapeutics, a biotech company listed under one-dollar stocks. Despite promising technologies, risks like financial runway ...
-
CytomX Therapeutics, Inc. (NASDAQ:CTMX) is definitely on the radar of institutional investors who own 47% of the company
By Yahoo! Finance | 4 months agoAnalyzing ownership data of a company like CytomX Therapeutics, Inc. can provide insights into future performance. Institutional investors hold a significant stake, influencing market decisions. Hedge...
-
Cytokinetics Sees IBD RS Rating Improve To 74
By Investor's Business Daily | 4 months agoIBD's RS Rating measures a stock's price performance, with high ratings indicating potential growth. Cytokinetics shows strength but is out of buy range. Look for new entry points. Check for upcoming ...
-
Cytotheryx looks to expand in Rochester and add 22 jobs
By Yahoo! Finance | 4 months agoThe Rochester City Council approved Cytotheryx's application for $870,000 state funding for a new lab building and 22 jobs. The company, co-founded by Exemplar Genetics and Mayo Clinic, plans to creat...
-
Cytora and Gamma Risk team to aid commercial property risk assessment
By Yahoo! Finance | 4 months agoCytora partners with Gamma Risk to integrate Perilfinder into its platform, enhancing insurers' risk assessment with advanced tools like address-level assessment and spatial catastrophe models. The co...
-
Nvidia, Pfizer lead $80 million funding for Israeli medical AI tech firm CytoReason
By Yahoo! Finance | 4 months agoCytoReason, an Israeli company using AI for disease models, raised $80 million in funding with investors like Nvidia and Pfizer. The company plans to expand its models, data, and open an office in Cam...